Astellas Pharma (Astellas Pharma) Cash-to-Debt : 0.33 (As of Dec. 2023)

View and export this data going back to 2008. Start your Free Trial

What is Astellas Pharma Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Astellas Pharma's cash to debt ratio for the quarter that ended in Dec. 2023 was 0.33.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Astellas Pharma couldn't pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Astellas Pharma's Cash-to-Debt or its related term are showing as below:

ALPMY' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.33 Med: No Debt Max: No Debt
Current: 0.33

During the past 13 years, Astellas Pharma's highest Cash to Debt Ratio was No Debt. The lowest was 0.33. And the median was No Debt.

ALPMY's Cash-to-Debt is ranked worse than
66.92% of 1049 companies
in the Drug Manufacturers industry
Industry Median: 0.95 vs ALPMY: 0.33

Astellas Pharma Cash-to-Debt Historical Data

The historical data trend for Astellas Pharma's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Astellas Pharma Cash-to-Debt Chart

Astellas Pharma Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Cash-to-Debt

Get a 7-Day Free Trial

No Debt

Astellas Pharma Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															No Debt	No Debt	1.68	0.41	0.33

Competitive Comparison of Astellas Pharma's Cash-to-Debt

For the Drug Manufacturers - General subindustry, Astellas Pharma's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Astellas Pharma's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Astellas Pharma's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Astellas Pharma's Cash-to-Debt falls into.

Astellas Pharma Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Astellas Pharma's Cash to Debt Ratio for the fiscal year that ended in Mar. 2023 is calculated as:

Astellas Pharma had no debt ⁽¹⁾.

Astellas Pharma's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	1982.449	/	(2827.981	+	3221.275)
	=	0.33

Astellas Pharma (OTCPK:ALPMY) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Astellas Pharma Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Astellas Pharma's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Astellas Pharma (Astellas Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Astellas Pharma Inc (OTCPK:ALPMY) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

ALPMF:USA 4503:Mexico 4503:Japan YPHA:Germany

Address

2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, JPN, 103-8411

Website

http://www.astellas.com

Astellas Pharma Inc is a drug manufacturing company that sells pharmaceutical products across the globe. The vast majority of the company's revenue is derived from Japanese markets, followed by the Americas. Royalty income makes up a small percentage of Astellas' overall sales. Its largest therapeutic area by sales composition is oncology, followed by urology and transplantation. The company uses mergers and acquisitions as part of its long-term growth strategy. Astellas enters into strategic partnerships and licensing agreements to strengthen its commercialization platforms.